- Erasca Inc TIMES tentatively announced Phase 1/1b monotherapy data for ERAS-007 and ERAS-601 in solid tumors.
- A retrospective pooled analysis of all studies evaluating ERAS-007 or ERAS-601 in advanced solid tumors included Erasca’s ongoing HERKULES-1 and FLAGSHP-1 studies and Asana BioSciences’ previously completed ASN007-101 study.
- Key results from the retrospective pooled interim analysis of ERAS-007 and ERAS-601 show that 23% (6/26) of solid tumor patients with RAS/MAPK-altered non-colorectal cancer (CRC) responded (2 confirmed and four unconfirmed PRs ) to the single agent ERAS-007 or ERAS-601.
- 44% (4/9) with a subset of BRAF-driven non-CRC solid tumors responded (1 confirmed and three unconfirmed PRs).
- ERAS-007 and ERAS-601 had favorable safety and tolerability profiles as monotherapy with largely non-overlapping treatment-emergent adverse events supporting combination development.
- Recently, Erasca announced a partnership with the University of Texas MD Anderson Cancer Center to evaluate multiple compounds in Erasca’s pipeline that target the RAS/MAPK pathway, either as single agents or as combination therapies.
- As part of the five-year agreement, collaborative preclinical and clinical studies will be conducted in NSCLC and gastrointestinal malignancies.
- The Company will initiate a dose escalation study of ERAS-007 in combination with ERAS-601 in H1 2023.
- Price promotion: ERAS shares are down 17.07% on the last check Thursday to $7.80.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
